The program, run through the Centers for Medicare & Medicaid Services (CMS), is tied to an executive order that reclassifies marijuana as a Schedule III substance. That’s the same category as Tylenol with codeine and anabolic steroids. In English: the federal government just moved cannabis from “no accepted medical use” to “yeah, doctors can probably work with this.”
Eligible Medicare beneficiaries can receive hemp-derived CBD products at no cost, provided they have a physician’s recommendation. The pilot covers around 34 million Medicare Advantage enrollees, which is a substantial slice of the senior population. If clinical outcomes look promising, the program could expand further.
